Liso-cel in r/r follicular lymphoma shows durable 3-year responses and favourable long-term safety

TKI chemotherapy and ponatinib improve survival outcomes in blast phase CML

Consolidation treatment delays do not compromise survival in MRD-negative adult ALL

Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC

Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma

Black patients show inferior survival despite similar cytogenetics and treatment response

Asciminib shows high molecular response, favourable safety in 2L CML-CP